BR0314541A - Tratamento de demência e doença de parkinson - Google Patents

Tratamento de demência e doença de parkinson

Info

Publication number
BR0314541A
BR0314541A BR0314541-7A BR0314541A BR0314541A BR 0314541 A BR0314541 A BR 0314541A BR 0314541 A BR0314541 A BR 0314541A BR 0314541 A BR0314541 A BR 0314541A
Authority
BR
Brazil
Prior art keywords
disease
parkinson
dementia
treatment
methods
Prior art date
Application number
BR0314541-7A
Other languages
English (en)
Portuguese (pt)
Inventor
William G Tatton
Larry A Wheeler
Daniel W Gil
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0314541A publication Critical patent/BR0314541A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
BR0314541-7A 2002-10-08 2003-10-07 Tratamento de demência e doença de parkinson BR0314541A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41703102P 2002-10-08 2002-10-08
PCT/US2003/031842 WO2004032934A1 (en) 2002-10-08 2003-10-07 Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons

Publications (1)

Publication Number Publication Date
BR0314541A true BR0314541A (pt) 2005-07-26

Family

ID=32093952

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314541-7A BR0314541A (pt) 2002-10-08 2003-10-07 Tratamento de demência e doença de parkinson

Country Status (20)

Country Link
US (1) US20040116436A1 (https=)
EP (1) EP1549314B1 (https=)
JP (1) JP2006504741A (https=)
KR (1) KR20050056235A (https=)
CN (1) CN100370988C (https=)
AT (1) ATE380551T1 (https=)
AU (2) AU2003279874A1 (https=)
BR (1) BR0314541A (https=)
CA (1) CA2501348A1 (https=)
DE (1) DE60318081T2 (https=)
ES (1) ES2297233T3 (https=)
HK (1) HK1080408B (https=)
IL (1) IL167848A (https=)
MX (1) MXPA05003665A (https=)
NO (1) NO20051664L (https=)
NZ (1) NZ539329A (https=)
PL (1) PL376347A1 (https=)
RU (1) RU2332218C2 (https=)
WO (1) WO2004032934A1 (https=)
ZA (1) ZA200502745B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
DE102009043750A1 (de) * 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
WO2016089997A1 (en) * 2014-12-02 2016-06-09 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота
US20210282643A1 (en) * 2016-08-01 2021-09-16 Cognoptix, Inc. System And Method For Detecting Tau Protein In Ocular Tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
MX9709112A (es) * 1995-05-26 1998-02-28 Pfizer Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
JP4783502B2 (ja) * 1997-12-04 2011-09-28 アラーガン、インコーポレイテッド α２Ｂまたは２Ｂ／２Ｃアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components

Also Published As

Publication number Publication date
AU2003279874A1 (en) 2004-05-04
HK1080408B (en) 2008-08-08
MXPA05003665A (es) 2005-06-08
ES2297233T3 (es) 2008-05-01
EP1549314B1 (en) 2007-12-12
JP2006504741A (ja) 2006-02-09
RU2332218C2 (ru) 2008-08-27
WO2004032934A1 (en) 2004-04-22
AU2010200730A1 (en) 2010-03-18
CN100370988C (zh) 2008-02-27
ZA200502745B (en) 2006-07-26
NZ539329A (en) 2007-11-30
DE60318081D1 (de) 2008-01-24
ATE380551T1 (de) 2007-12-15
KR20050056235A (ko) 2005-06-14
PL376347A1 (en) 2005-12-27
NO20051664L (no) 2005-05-31
CN1703222A (zh) 2005-11-30
EP1549314A1 (en) 2005-07-06
HK1080408A1 (en) 2006-04-28
US20040116436A1 (en) 2004-06-17
CA2501348A1 (en) 2004-04-22
RU2005114505A (ru) 2005-10-27
IL167848A (en) 2010-11-30
DE60318081T2 (de) 2008-11-06

Similar Documents

Publication Publication Date Title
NO20034056D0 (no) Proliferative sykdommer
DE60132777D1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
GB0223038D0 (en) Therapeutic compounds
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DK0721449T3 (da) Inhibitorer af beta-amyloidproteinproduktion
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
GB0225474D0 (en) Therapeutic agents
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
NO20021541D0 (no) 5-beta-sapogenin- og pseudossapogeninderivater samt deres anvendelse ved behandling av demens
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
ATE427928T1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
BR0314541A (pt) Tratamento de demência e doença de parkinson
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
DE60327335D1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.